Sleep Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.

The professor of neurology at Washington University School of Medicine in St. Louis spoke about the field of newborn sleep and epilepsy based on a special lecture from the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

Advanced practice practitioners discuss how they assess treatment response and patient adherence in insomnia, and considerations for changing treatment.

Drs Wendy Wright and Debra Davis provide an overview of phase 3 trial data for the most recently FDA-approved DORA, daridorexant, for the treatment of insomnia.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Advanced practice practitioners discuss dual orexin receptor antagonists (DORAs) suvorexant, lemborexant, and daridorexant for the treatment of sleep disorders.

Wendy Wright and Debra Davis provide an overview of pathways and neurotransmitters involved in sleep and wake cycles.

A recent cross-sectional analysis showed an increase in coded diagnoses of insomnia during pregnancy in the United States over time.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 25, 2022.

Nearly 40% of patients treated with CBT-I met the Athens Insomnia Score criteria for remission after 8 weeks of treatment compared with slightly above 10% of those on sham.

In a bidirectional Mendelian randomization analysis, findings revealed an association with obstructive sleep apnea and severe COVID-19 that were suggestive of a causal relationship.

Dr Wendy Wright and Debra Davis review treatment options for sleep disorders, including benzodiazepines, z-drugs, and dual orexin receptor antagonists (DORAs) and their treatment selection criteria.

Advanced nurse practitioners talk about the importance of early diagnosis of insomnia and other sleep disorders.

A sleep study on adolescents and their insomnia symptoms showed that those with a shorter sleep duration experienced deficient executive functions in daily life.

An expert in sleep medicine highlights challenges in prescribing DORAs and importance of discussing insomnia with patients in the primary care setting.

Dr Paul Doghramji shares his approach to switching medications for the treatment of insomnia.

Paul Doghramji, MD, FAAFP, shares his personal experience with DORAs in clinical practice to manage insomnia and discusses treatment adherence with insomnia medications.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 18, 2022.

Charlene Gamaldo, MD, discusses patient criteria for selecting a dual orexin receptor agonist (DORA) for insomnia treatment.

An overview of dual orexin receptor agonists (DORAs) therapy for the treatment of insomnia in female patients.